-
Alipogene tiparvovec, sold
under the
brand name Glybera, is a gene
therapy treatment designed to
reverse lipoprotein lipase deficiency (LPLD), a rare...
- approval.
Since that time,
further gene
therapy drugs were approved, such as
alipogene tiparvovec (2012),
Strimvelis (2016),
tisagenlecleucel (2017), voretigene...
-
United States in
December 2024. In 2012, the
European Commission approved alipogene tiparvovec (Glybera), a gene
therapy for
adults with
familial LPLD (confirmed...
-
Peptides and
glycopeptides nesiritide,
octreotide -vec Gene
therapy vectors Alipogene tiparvovec -ast Anti-asthmatic zafirlukast,
seratrodast -caine
local anesthetic...
-
chronic lymphocytic leukemia (CLL), and Parkinson's disease. In 2012,
Alipogene tiparvovec became the
first gene
therapy treatment to be
approved for...
- used in
basic neuroscience research.
Following the
approval of the AAV
Alipogene tiparvovec in
Europe in 2012, in 2017, the FDA
approved the
first AAV-based...
- This
article contains a list of
commercially available gene therapies.
Alipogene tiparvovec (Glybera): AAV-based
treatment for
lipoprotein lipase deficiency...
-
pyridoxal 5-phosphate
glutamate C10AX08
Policosanol C10AX09
Ezetimibe C10AX10
Alipogene tiparvovec C10AX11
Mipomersen C10AX12
Lomitapide C10AX13 Evolo****ab C10AX14...
-
alinastine (INN)
Alinia (Romark Laboratories)
alinidine (INN)
alipamide (INN)
alipogene tiparvovec (INN)
alisertib (INN, USAN)
aliskiren (USAN)
alisporivir INN...
- C,
Tremblay G, et al. (April 2013). "Efficacy and long-term
safety of
alipogene tiparvovec (AAV1-LPLS447X) gene
therapy for
lipoprotein lipase deficiency:...
